Sure it does. The manufacturer’s agree that monoclonal antibody treatment does not work on omicron. The use of MAT as a mass treatment for all positive COVID is therefore medically unsupported. On the other hand, as noted elsewhere here, MAT is effective on Delta variant. The FDA rule therefore preserves the treatment for those who actually need it, and disallows the use at mass treatment sites, but not as individually prescribed for Delta and other non-omicron variants.
The problem is the undifferentiated use on a mass scale for variants where there is no medical justification. By the way, I note that this only applies to two MAT’s and not to the one that is effective against omicron.
As far as i know, it was always reserved for the most at risk. Now it’s none here. They gave it to us due to comorbidities. But the minister’s wife is about the same as us.